Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation

Jackie Queen, Emily Limerick, Neal Jeffries, Ritika Menon, Matthew M. Hsieh, Robert Shamburek, Courtney D. Fitzhugh

Blood (2023) 142 (Supplement 1): 929.

https://doi.org/10.1182/blood-2023-186341

Published: 2023

Journal Articles

Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism

Rialnat A. Lawal, Devdeep Mukherjee, Emily M. Limerick, Wynona Coles, Matthew M. Hsieh, Laura W. Dillon, Christopher S. Hourigan, Courtney D. Fitzhugh

Blood (2022) 140 (23): 2514–2518.

https://doi.org/10.1182/blood.2022017960

Published: 2022

Journal Articles

Pulmonary Function before and after Hematopoietic Cell Transplant in People Living with Sickle Cell Disease

Amy Parker Ruhl, Ruba Shalhoub, Neal Jeffries, Alexis Leonard, Emily Limerick, Amisha Barochia, Matthew M. Hsieh, Courtney D. Fitzhugh

Blood (2022) 140 (Supplement 1): 8294–8295.

https://doi.org/10.1182/blood-2022-157235

Published: 2022

Journal Articles

Phenotypic Screening of the Reframe Drug Repurposing Library to Discover New Drugs for Treating Sickle Cell Disease

William A. Eaton, Belhu Metaferia, Troy Cellmer, Emily B. Dunkelberger, Quan Li, Eric R. Henry, James Hofrichter, Dwayne Staton, Matthew M. Hsieh, Anna Conrey, John Tisdale, Arnab K. Chatterjee, Swee Lay Thein

Blood (2022) 140 (Supplement 1): 11089–11090.

https://doi.org/10.1182/blood-2022-159634

Published: 2022

Journal Articles

Pentostatin Plus Cyclophosphamide Decrease Graft Rejection in Nonmyeloablative Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease

Emily Limerick, Mary Lacy Grecco, Julia Varga, Jennifer Brooks, Wynona Coles, R. AdeBisi Lawal, Neal Jeffries, Matthew M. Hsieh, Courtney D. Fitzhugh

Blood (2022) 140 (Supplement 1): 7572–7573.

https://doi.org/10.1182/blood-2022-169796

Published: 2022

Journal Articles

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT

Emily Limerick, Santosh L. Saraf, Neal Jeffries, Farah O'Boyle, Clarissa Diamantidis, Yuliya Lokhnygina, Matthew M. Hsieh, Josu de la Fuente, Courtney D. Fitzhugh

Blood (2021) 138 (Supplement 1): 984.

https://doi.org/10.1182/blood-2021-153230

Published: 2021

Journal Articles

Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Emily Limerick, MD, Neal Jeffries, PhD, Clarissa Diamantidis, MD, Yuliya Lokhnygina, PhD, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD

Blood (2020) 136 (Supplement 1): 58–59.

https://doi.org/10.1182/blood-2020-142630

Published: 2020

Journal Articles

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation

Jack Y. Ghannam, Xin Xu, Irina Maric, Laura Dillon, Yuesheng Li, Matthew M. Hsieh, Christopher S. Hourigan, Courtney D. Fitzhugh

Blood (2020) 135 (14): 1185–1188.

https://doi.org/10.1182/blood.2019004001

Published: 2020

Journal Articles

Selective Proliferation of Gene-Modified Human Erythroid Cells with Truncated Erythropoietin Receptors

Naoya Uchida, MD PhD, Anna Shvygin, Lydia Raines, Juan Jesus J. Haro Mora, PhD, Selami Demirci, PhD, Matthew M. Hsieh, MD, John F Tisdale, MD

Blood (2017) 130 (Supplement 1): 3338.

https://doi.org/10.1182/blood.V130.Suppl_1.3338.3338

Published: 2017

Journal Articles

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Courtney D. Fitzhugh, Stefan Cordes, Tiffani Taylor, Wynona Coles, Katherine Roskom, Mary Link, Matthew M. Hsieh, John F. Tisdale

Blood (2017) 130 (17): 1946–1948.

https://doi.org/10.1182/blood-2017-03-772392

Published: 2017

Includes: Supplemental data

Journal Articles

Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders

Naoya Uchida, MD PhD, Matthew M. Hsieh, MD, Aylin C Bonifacino, Allen E Krouse, Mark E Metzger, Robert E Donahue, John F. Tisdale, MD

Blood (2016) 128 (22): 1172.

https://doi.org/10.1182/blood.V128.22.1172.1172

Published: 2016

Journal Articles

Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease

Julie Kanter, MD, Mark C. Walters, MD, Matthew M. Hsieh, MD, Lakshmanan Krishnamurti, MD, Janet Kwiatkowski, MD, Rammurti T Kamble, MD, Christof von Kalle, MD, Frans A. Kuypers, PhD, Marina Cavazzana, MD PhD, Philippe Leboulch, MD, Marcelyne Joseney-Antoine, Mohammed Asmal, MD PhD, Alexis A. Thompson, MD MPH, John F. Tisdale, MD

Blood (2016) 128 (22): 1176.

https://doi.org/10.1182/blood.V128.22.1176.1176

Published: 2016

Journal Articles

Immunohematologic Complications after Nonmyeloablative Hematopoietic Progenitor Cell Transplantation in Patients with Sickle Cell Disease

Elizabeth S. Allen, MD, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD, Harvey G. Klein, MD, John F. Tisdale, MD, Willy A. Flegel

Blood (2016) 128 (22): 3404.

https://doi.org/10.1182/blood.V128.22.3404.3404

Published: 2016

Journal Articles

A Novel Recombinant Eklf-GATA1 Fusion Protein Reduces Sickling of Erythrocytes Cultured from CD34 + Cells with Sickle Cell Disease

Jianqiong Zhu, Kyung Chin, Wulin Aerbajinai, MD PhD, Chutima Kumkhaek, PhD, Hongzhen Li, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD, Griffin P. Rodgers, MD

Blood (2016) 128 (22): 3506.

https://doi.org/10.1182/blood.V128.22.3506.3506

Published: 2016

Journal Articles

At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation

Courtney D. Fitzhugh, MD, Matthew M. Hsieh, MD, Stefan Cordes, MD, Tiffani Taylor, PA, Wynona Coles, MPH, Katherine Roskom, RN, John F. Tisdale, MD

Blood (2016) 128 (22): 2483.

https://doi.org/10.1182/blood.V128.22.2483.2483

Published: 2016

Journal Articles

Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease

Atsushi Fujita, MD, PhD, Courtney D. Fitzhugh, MD, Matthew M. Hsieh, MD, John F. Tisdale, MD, Naoya Uchida, MD, PhD

Blood (2013) 122 (21): 2209.

https://doi.org/10.1182/blood.V122.21.2209.2209

Published: 2013

Journal Articles

Therapeutic Hydroxyurea Dosing Is Associated With Decreased Organ Damage and Longer Survival In Adults With Sickle Cell Anemia

Courtney Fitzhugh, MD, Darlene Allen, MT(ASCP), Wynona Coles, RRT, Michael Ring, MD, Xiongce Zhao, PhD, Matthew M. Hsieh, MD, James G Taylor, MD

Blood (2013) 122 (21): 2228.

https://doi.org/10.1182/blood.V122.21.2228.2228

Published: 2013

Journal Articles

Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Helen Gharwan, MD, DSc, Courtney Fitzhugh, MD, Mary Link, RN, Wynona Coles, RRT, Deborah Citrin, MD, John F. Tisdale, MD, Matthew M. Hsieh, MD

Blood (2013) 122 (21): 4646.

https://doi.org/10.1182/blood.V122.21.4646.4646

Published: 2013

Journal Articles

Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors

Sandhya R. Panch, MD, MPH, Yu Ying Yau, RN, Courtney Fitzhugh, MD, Matthew M. Hsieh, MD, John F. Tisdale, MD, Charles D. Bolan, Jr., MD, Susan F. Leitman, MD

Blood (2013) 122 (21): 696.

https://doi.org/10.1182/blood.V122.21.696.696

Published: 2013

Journal Articles

MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34 + cells through the Raf/MEK/ERK pathway

Chutima Kumkhaek, Wulin Aerbajinai, Wenli Liu, Jianqiong Zhu, Naoya Uchida, Roger Kurlander, Matthew M. Hsieh, John F. Tisdale, Griffin P. Rodgers

Blood (2013) 121 (16): 3216–3227.

https://doi.org/10.1182/blood-2011-10-385252

Published: 2013

Includes: Supplemental data

NARROW

SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation

Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism

Pulmonary Function before and after Hematopoietic Cell Transplant in People Living with Sickle Cell Disease

Phenotypic Screening of the Reframe Drug Repurposing Library to Discover New Drugs for Treating Sickle Cell Disease

Pentostatin Plus Cyclophosphamide Decrease Graft Rejection in Nonmyeloablative Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT

Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation

Selective Proliferation of Gene-Modified Human Erythroid Cells with Truncated Erythropoietin Receptors

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders

Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease

Immunohematologic Complications after Nonmyeloablative Hematopoietic Progenitor Cell Transplantation in Patients with Sickle Cell Disease

A Novel Recombinant Eklf-GATA1 Fusion Protein Reduces Sickling of Erythrocytes Cultured from CD34 + Cells with Sickle Cell Disease

At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation

Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease

Therapeutic Hydroxyurea Dosing Is Associated With Decreased Organ Damage and Longer Survival In Adults With Sickle Cell Anemia

Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors

MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34 + cells through the Raf/MEK/ERK pathway

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only